GALE-302: Additional Phase IIa data

Data from 17 HLA-A2-positive patients with endometrial or ovarian cancer who completed the Phase IIa portion evaluating 6 monthly injections of intradermal GALE-301 plus GM-CSF and

Read the full 264 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE